When Product Quality Becomes a State AG Issue: Texas’s Expanding Scrutiny of Consumer-Health Claims

Introduction

Texas’s industry-wide investigation into protein powder manufacturers is not just a supplement story. It is the latest example of a broader state-law enforcement pattern: state Attorneys General increasingly will take on consumer-protection matters in response to consumer perception of potential safety concerns for various consumer products.

That shift extends beyond supplements. Any product marketed with health, safety, purity, or family-oriented messaging may draw similar scrutiny.

The Protein Powder Development

On June 8, 2026, as a noteworthy example, the Texas Attorney General Ken Paxton announced an industry-wide investigation into protein powder manufacturers based on concerns about heavy metals, including lead and cadmium, in popular protein powders. The announcement cited testing by Consumer Reports and the Clean Label Project and highlighted alleged heavy-metal concerns in products marketed for nutrition, wellness, and health.

The investigation is notable because it is not limited to a single company or claim. It is framed as industry-wide. Industry-wide investigations often begin with public testing, consumer concern, advocacy reports, or a prominent media hook, then expand into requests for product testing records, supplier documentation, substantiation files, complaint data, and internal risk assessments.

The immediate question is practical: if a State AG asked tomorrow how the product is tested, what the company knows about contaminants, and how consumers understand related claims, could the company answer clearly and with documentation?

Proposition 65 as the Canary in the Coal Mine

For companies that have dealt with California Proposition 65, the Texas protein powder investigation should feel familiar. Prop 65 enforcement has targeted these same heavy metals for years.

Lead, cadmium, arsenic, and other heavy metals in food and dietary supplements have long driven Prop 65 notices, settlements, and consent judgments. Prop 65 regulations and the private-enforcement mechanism under Prop 65 has generated a substantial body of settlements establishing acceptable daily intake levels for heavy metals in a wide variety of consumer products. Those settlements did not just resolve individual cases. They created industry benchmarks that regulators, plaintiffs’ counsel, consumer advocacy groups, and testing labs now treat as reference points for what companies knew, or should have known, about contamination levels in their products.

That is why Prop 65 functions as a canary in the coal mine. A Prop 65 notice is often the first formal sign that a product has drawn regulatory attention. When companies treat a Prop 65 notice as a narrow labeling exercise they may miss the larger message. The same contaminant data that triggered the Prop 65 notice can later surface in a State AG investigation, an FDA enforcement action, a Consumer Reports study, or a class action complaint. A warning that resolves a Prop 65 matter may also be used to argue that the company knew of the issue and chose labeling over reformulation.

That is why companies receiving a Prop 65 notice should evaluate the full range of corrective options, not just warnings. Companies that treat Prop 65 as a narrow labeling exercise risk missing the broader exposure. Reformulation, supplier changes, or enhanced testing may be more protective than a warning that highlights the issue. A compliant warning under California law does not insulate a company from a Texas AG inquiry or potential FDA scrutiny where contaminant levels raise safety concerns.

The Broader Texas Signal

The protein powder investigation did not arrive in isolation. In the same week, Texas announced an investigation into Celsius Holdings and Alani Nutrition regarding representations and practices involving energy drinks marketed to teens and children. Texas also announced legal action as part of a sweeping investigation involving glyphosate residue in food, including civil investigative demands to major pesticide and food manufacturers.

Taken together, those three June 2026 actions suggest a focused interest in consumer-health products where science, safety, marketing, children or families, and consumer trust intersect.

The lookback is broader than June 2026. Over the past several years, Texas has announced actions involving:

• Major baby food manufacturers and alleged heavy metals in baby food;
• Colgate-Palmolive and Crest toothpaste agreements concerning children and fluoride exposure;
• Kellogg’s and artificial dyes in cereal;
• Manufacturers of household products allegedly with PFAS or “forever chemicals” being advertised as safe for families;
• Lululemon and the potential presence of PFAS in activewear;
• Shein and alleged toxic products, among other issues;
• Johnson & Johnson and a multistate settlement involving alleged misleading safety claims concerning talc-based baby powder; and
• CarMax and a multistate settlement over disclosure of safety recalls.

These matters are not identical. Some are investigations. Some are lawsuits. Some are agreements or multistate settlements. Some involve children. Some involve food. Some involve household products, apparel, autos, or personal-care products. But the through line is commercially important: State AGs can use consumer-protection tools to scrutinize the relationship between what a product is, how it is tested, how it is marketed, and how consumers understand its safety or quality.

Why State AGs Are Focused on This

Health or safety issues for consumer products are especially attractive right now to State AGs for several reasons.

First, they are easy to explain. Lead, cadmium, arsenic, PFAS, fluoride exposure, caffeine levels, artificial dyes, and safety recalls are not abstract regulatory issues. They are concrete and understandable to consumers, reporters, legislators, and courts.

Second, they often involve consumer trust. Consumers buy food, household, and wellness products with assumptions about safety, purity, health, or performance. A regulator does not need to prove that every consumer read every word of a label to ask whether the overall presentation created a misleading impression.

Third, they can involve vulnerable or politically salient consumers: children, teens, parents, families, health-conscious consumers, and consumers using products for nutrition, fitness, wellness, or safety.

Fourth, these issues often have a supply-chain dimension. A brand may rely on ingredient suppliers, contract manufacturers, third-party labs, private-label arrangements, retailers, marketplaces, advertising agencies, influencers, or affiliates. That complexity can create factual questions about who knew what, who tested what, who approved what, and who was responsible for warnings, disclosures, recalls, or remediation.

Fifth, they connect public signals with internal records. Public testing, advocacy reports, and media coverage can create immediate pressure. AG investigations then focus on whether the company’s internal data, testing, and decision-making align with those public signals.

Finally, Prop 65 settlements and consent judgments provide a ready-made record for comparison. They identify contaminants, products, exposure levels, and agreed corrective actions. For regulators, that record functions as a baseline for assessing prior knowledge and response. A company’s Prop 65 history is not just a California compliance issue. It is a discoverable record that can be used to evaluate what the company knew, how it responded, and whether similar risks were addressed consistently across products and markets.

Why Traditional Consumer-Protection Authority Is Enough

The important point is that State AGs do not need a protein-powder statute, a caffeine statute, or a PFAS-in-activewear statute to investigate many of these issues. Traditional consumer-protection authority is often enough to ask whether a company’s labels, claims, omissions, packaging, disclosures, or practices were unfair, deceptive, misleading, or otherwise unlawful.

That authority can reach well beyond express claims. AGs may ask about the full consumer impression created by:

• product names and front-label statements;
• “clean,” “natural,” “safe,” “healthy,” “pure,” or family-oriented language;
• images, colors, mascots, flavors, or design elements that may appeal to children;
• serving sizes, dosage depictions, or usage illustrations;
• third-party certifications or testing seals;
• social media, influencer, and affiliate claims;
• retailer and marketplace descriptions;
• omission of known testing, contaminant, or safety information; and
• complaint handling, refunds, adverse-event reports, and remediation.

That is why the protein powder investigation matters beyond supplements. It reflects a broader enforcement question: when does a product-quality issue become a consumer-protection issue? For State AGs, the answer may depend less on the product category than on the combination of consumer expectations, product representations, testing data, internal knowledge, and public-health salience.

What Companies Should Be Able to Explain

Companies in the consumer products ecosystem should assume that an AG inquiry may move quickly from public-facing claims to a company’s operational evidence. Before a civil investigative demand (“CID”) arrives, companies should be able to explain:

• how product claims are substantiated;
• what testing is performed, by whom, and how often;
• how ingredient suppliers, contract manufacturers, and private-label partners are vetted;
• what the company knows about contaminants, impurities, or safety concerns;
• how labels, warnings, and instructions are reviewed;
• how marketing claims are controlled across websites, retailers, marketplaces, affiliates, and influencers;
• how consumer complaints, adverse events, returns, refund requests, and online reviews are tracked;
• how the company decides whether to change a label, reformulate, issue a warning, notify a retailer, or remediate a consumer issue;
• whether prior testing, complaints, litigation, or regulator inquiries have been escalated and addressed.
• whether the company has received Prop 65 notices of violation, and how those matters were resolved — including whether the company chose to warn, reformulate, or both.
• whether Prop 65 settlement levels or consent judgment thresholds informed the company’s ongoing product testing and reformulation decisions.

whether FDA regulatory or guidance thresholds for contaminants have been incorporated into the company’s compliance framework — and how the company reconciles those thresholds with Prop 65 safe harbor levels, which may differ.

The companies best positioned for this environment will not be those that can point only to general compliance policies. They will be those that can show how their products are actually tested, marketed, monitored, and corrected when problems arise.

What This Means for Product Liability and State AG Risk

Product liability and State AG consumer-protection risk are distinct, but they increasingly overlap. Product liability focuses on injury, causation, warnings, and defect. State AGs focus on public representations, testing, disclosures, consumer impression, and complaint patterns. The same product can raise both sets of questions at the same time.

That overlap matters. A product allegations can create simultaneous exposure through private litigation, AG enforcement, legislative interest, and reputational risk. The same documents may matter to all of them, but the questions are different.

For companies, that means response strategies should not be siloed. A companies response teams should understand that an AG inquiry is not only a request for legal analysis. It is also a test of the company’s ability to explain its product story credibly.

FDA enforcement adds a third layer. For food and dietary supplement companies, the same contaminant issue can trigger State AG scrutiny, Proposition 65 exposure, and FDA enforcement. FDA may evaluate products under adulteration standards, action levels, guidance levels, risk assessments, and other safety-based frameworks, even without a fixed federal limit.

The FDA inquiry goes beyond the test results. FDA often focuses on how the company managed the issue: are appropriate specifications established, are the suppliers qualified, is testing adequate, are there out-of-specification findings, are quality-control records maintained, and were effective corrective actions implemented.

Companies that treat Proposition 65, FDA compliance, and State AG risk as separate silos may find themselves defending the same issue under different standards. More effective programs evaluate contaminant risk holistically and align testing, supplier management, reformulation, and labeling decisions across all three.

Buchalter’s Perspective

The Texas investigation is a reminder that State AG risk is not limited to financial services or classic fraud. Consumer products of all kinds can draw scrutiny when product composition, testing, labeling, or safety claims are questioned.

Companies should not wait for an AG inquiry to assemble the record. They should be prepared now to explain how their products are tested, marketed, and monitored.

Buchalter’s State Attorneys General, Product Liability, Consumer Products, White Collar and Investigations, and regulatory teams represent companies in investigations, enforcement actions, and related litigation. We help clients assess risk early, respond to CIDs and subpoenas, and present clear explanations of product testing, labeling, and remediation practices. Our experience with Proposition 65, FDA regulatory frameworks, and multistate AG enforcement provides a coordinated approach to managing overlapping risks.

Companies with questions about consumer-product risk should contact the authors.

This communication is not intended to create or constitute, nor does it create or constitute, an attorney-client or any other legal relationship. No statement in this communication constitutes legal advice nor should any communication herein be construed, relied upon, or interpreted as legal advice. This communication is for general information purposes only regarding recent legal developments of interest, and is not a substitute for legal counsel on any subject matter. No reader should act or refrain from acting on the basis of any information included herein without seeking appropriate legal advice on the particular facts and circumstances affecting that reader. For more information, visit www.buchalter.com.